Insmed, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$40.1M
Doctors Paid
12,303
Transactions
89,291
2024 Total
$8.3M
Payment Breakdown by Category
Research$31.5M (78.6%)
Consulting$2.8M (7.1%)
Food & Beverage$1.6M (3.9%)
Travel$713,447 (1.8%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $31.5M | 16,267 | 78.6% |
| Consulting Fee | $2.8M | 1,324 | 7.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.7M | 915 | 4.3% |
| Food and Beverage | $1.6M | 61,764 | 3.9% |
| Grant | $1.4M | 28 | 3.4% |
| Travel and Lodging | $713,447 | 2,015 | 1.8% |
| Education | $231,747 | 6,881 | 0.6% |
| Space rental or facility fees (teaching hospital only) | $153,190 | 97 | 0.4% |
Payments by Type
Research
$31.5M
16,267 transactions
General
$8.6M
73,024 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | $14.2M | 9 | 4,718 |
| A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study | $5.6M | 3 | 6,834 |
| A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (ARISE) | $4.8M | 0 | 2,224 |
| Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Study to Assess the Efficacy, Safety & Tolerability, and PK of INS1007 Administered Once Daily for 24 Weeks in Subjects With Non-CF Bronchiectasis - The Willow Study | $1.5M | 0 | 335 |
| A Phase 2a, Single-Blind, Placebo-Controlled, Parallel-Group Study to Assess Safety, Tolerability, and Pharmacokinetics of Brensocatib Tablets in Adults With Cystic Fibrosis | $1.1M | 0 | 264 |
| ARISE - A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (MAC) | $1.0M | 0 | 725 |
| ENCORE - A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (MAC) | $892,631 | 0 | 504 |
| A Phase 2b, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Arterial Hypertension | $407,213 | 0 | 92 |
| A Randomized, Open-label, Multicenter Study of Liposomal Amikacin for Inhalation (LAI) in Adult Patients With Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (MAC) That Are Refractory to Treatment | $347,039 | 0 | 101 |
| A Phase 2, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Safety and Tolerability of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease | $279,863 | 1 | 92 |
| INS1007-102 | $274,849 | 0 | 24 |
| An Open-Label Safety Extension Study to a Multicenter Study of Liposomal Amikacin for Inhalation (LAI) in Adult Patients With Nontuberculous Mycobacterial (NTM) Lung Infections Caused by Mycobacterium Avium Complex (MAC) That Are Refractory to Treatment | $267,005 | 0 | 114 |
| An Open-Label Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Arterial Hypertension | $209,977 | 0 | 49 |
| A Study to Assess the Safety, Tolerability, and Effectiveness of the Long-Term Use of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Arterial Hypertension (PAH) | $159,774 | 0 | 25 |
| An Extension Study to Assess the Safety, Tolerability, and Effectiveness of the Long-Term Use of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD) | $121,797 | 6 | 48 |
| OHSU Biobank: The Oregon nontuberculous mycobacteria (NTM) cohort; immune correlates of pulmonary NTM disease progression | $108,653 | 0 | 3 |
| Insmed BIRCH Study | $49,295 | 8 | 51 |
Payments by Medical Specialty
Top Paid Doctors — Page 4
| Doctor | Specialty | Location | Total | 2024 |
|---|---|---|---|---|
| Scott Rojas, M.d, M.D | Infectious Disease | Panama City, FL | $17,814 | $0 |
| Jeffrey Sager, Md, MD | Critical Care Medicine | Santa Barbara, CA | $17,573 | $0 |
| Bryan Garcia | Pulmonary Disease | Birmingham, AL | $17,278 | $0 |
| Francis Averill, Md, MD | Pulmonary Disease | Clearwater, FL | $17,001 | $0 |
| Raymond Benza, Md, MD | Cardiovascular Disease | Norfolk, VA | $15,789 | $0 |
| Dr. Silvania Ng, Md, MD | Infectious Disease | Cincinnati, OH | $15,555 | $0 |
| Joshiah Gordon, D.o, D.O | Pulmonary Disease | Pueblo, CO | $15,340 | $0 |
| Beata Casanas, M.d, M.D | Infectious Disease | Tampa, FL | $15,335 | $0 |
| Dr. Mary Daniels, M.d., M.p.h, M.D., M.P.H | Internal Medicine | Chapel Hill, NC | $15,142 | $0 |
| Rajan Saggar, Md, MD | Pulmonary Disease | Los Angeles, CA | $14,997 | $0 |
| Fortune Alabi, Md, MD | Pulmonary Disease | Kissimmee, FL | $14,953 | $0 |
| Dr. Boris Sagalovich, Md, MD | Pulmonary Disease | Brooklyn, NY | $14,790 | $0 |
| Cheryl Mcdonald, M.d, M.D | Infectious Disease | Fort Worth, TX | $14,720 | $0 |
| Mr. Tony Hodges, M.d, M.D | Pulmonary Disease | Phoenix, AZ | $14,708 | $0 |
| Adam Smith, Md, MD | Critical Care Medicine | Burlington, MA | $14,698 | $0 |
| Dr. Jana Preis, Md, Mph, MD, MPH | Infectious Disease | Forest Hills, NY | $14,697 | $0 |
| Dr. Farjad Sarafian, Md, MD | Infectious Disease | Irvine, CA | $14,497 | $0 |
| Dr. Elizabeth Talbot, Md, MD | Infectious Disease | Lebanon, NH | $13,968 | $0 |
| Dr. Aaron Waxman, M.d., Ph.d, M.D., PH.D | Internal Medicine | Boston, MA | $13,800 | $0 |
| Dr. Takkin Lo, M.d, M.D | Pulmonary Disease | Honolulu, HI | $13,580 | $0 |
| Jeff Hales, Md, MD | Pulmonary Disease | Arlington, VA | $13,507 | $0 |
| David Margolis, Md, MD | Dermatology | Philadelphia, PA | $13,440 | $0 |
| Dr. Gifford Lorenz, M.d, M.D | Pulmonary Disease | Savannah, GA | $13,424 | $0 |
| Dr. Chaim Bernstein, M.d, M.D | Pulmonary Disease | Brooklyn, NY | $13,372 | $0 |
| Dr. Chad Marion, Do, DO | Critical Care Medicine | Winston Salem, NC | $12,889 | $0 |
About Insmed, Inc.
Insmed, Inc. has made $40.1M in payments to 12,303 healthcare providers, recorded across 89,291 transactions in the CMS Open Payments database. In 2024, the company paid $8.3M. The top product by payment volume is Arikayce ($23.0M).
Payments were distributed across 138 medical specialties. The top specialty by payment amount is Pulmonary Disease ($3.1M to 2,478 doctors).
Payment categories include: Food & Beverage ($1.6M), Consulting ($2.8M), Research ($31.5M), Travel & Lodging ($713,447).
Insmed, Inc. is associated with 2 products in the CMS Open Payments database.